HomeCompareSTAEY vs ABBV

STAEY vs ABBV: Dividend Comparison 2026

STAEY yields 1.13% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.2K in total portfolio value
10 years
STAEY
STAEY
● Live price
1.13%
Share price
$11.20
Annual div
$0.13
5Y div CAGR
21.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$998.21
Full STAEY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — STAEY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTAEYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STAEY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STAEY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STAEY
Annual income on $10K today (after 15% tax)
$96.34/yr
After 10yr DRIP, annual income (after tax)
$848.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,207.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STAEY + ABBV for your $10,000?

STAEY: 50%ABBV: 50%
100% ABBV50/50100% STAEY
Portfolio after 10yr
$63.7K
Annual income
$12,884.99/yr
Blended yield
20.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

STAEY
No analyst data
Altman Z
3.3
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STAEY buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTAEYABBV
Forward yield1.13%3.06%
Annual dividend / share$0.13$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR21.8%40.6%
Portfolio after 10y$25.1K$102.3K
Annual income after 10y$998.21$24,771.77
Total dividends collected$4.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: STAEY vs ABBV ($10,000, DRIP)

YearSTAEY PortfolioSTAEY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,838$138.05$11,550$430.00$712.00ABBV
2$11,767$170.31$13,472$627.96$1.7KABBV
3$12,801$210.49$15,906$926.08$3.1KABBV
4$13,958$260.66$19,071$1,382.55$5.1KABBV
5$15,259$323.52$23,302$2,095.81$8.0KABBV
6$16,729$402.59$29,150$3,237.93$12.4KABBV
7$18,403$502.44$37,536$5,121.41$19.1KABBV
8$20,320$629.15$50,079$8,338.38$29.8KABBV
9$22,533$790.79$69,753$14,065.80$47.2KABBV
10$25,109$998.21$102,337$24,771.77$77.2KABBV

STAEY vs ABBV: Complete Analysis 2026

STAEYStock

Stanley Electric Co., Ltd., together with its subsidiaries, manufacture, sells, and import/export of automotive and other light bulbs. It operates through Automotive Equipment, Electronic Components, and Applied Electronic Products segments. The Automotive Equipment Business segment offers LED, HID, and halogen headlamps; rear combination, turn signal, and fog lamps; and automotive LED and light bulbs, etc. The Electronic Components Business segment provides ultraviolet (UV), visible light, and infrared LEDs; optical sensors, liquid crystal display (LCD) devices, and UV cold cathode lamps; and sub miniature lamps, etc. The Applied Electronic Products Business segment offers LED lighting for landscape, road, etc.; operating panels; backlighting units for LCDs; flash units for cameras; and sensors for automobiles, etc. The company also offers measuring instruments, medical equipment, and other equipment, as well as develops and sells software. It operates in Japan, the Americas, the Asia-Pacific, China, and internationally. Stanley Electric Co., Ltd. was founded in 1920 and is headquartered in Tokyo, Japan.

Full STAEY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this STAEY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STAEY vs SCHDSTAEY vs JEPISTAEY vs OSTAEY vs KOSTAEY vs MAINSTAEY vs JNJSTAEY vs MRKSTAEY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.